TRW & Co · Trade, Regulation & ESG
Life Sciences Licensing in Singapore
Life sciences licensing in Singapore moves drug candidates, biologics, diagnostics and research tools from inventors to developers. A sound licence rests on clean patent title, lawful use of samples and data, and a clear answer to who will hold product registrations. This guide explains the framework, deal structures, key terms and the mistakes that most often undermine value.
Key pointHSA requires a local company to hold each therapeutic product registration and to make a patent declaration, so a licence that is silent on Singapore registration ownership leaves a key asset to whoever happens to file first.
At a glance
20-year patent term
Singapore patents last 20 years from filing, extendable where an extension is granted, with renewal fees payable annually from the fourth anniversary.
Local registrant required
Applicants for therapeutic product registration with HSA must be local ACRA-registered companies, so licences must allocate Singapore registration ownership.
Patent declaration at filing
Regulation 23 of the Therapeutic Products Regulations requires applicants to declare whether a subsisting patent would restrain supply of the product.
No commercial tissue trading
The Human Biomedical Research Act framework aims to prevent commercial trading in human tissue, limiting how samples can be licensed.
Restoration within 18 months
A patent that lapses for non-payment can be restored within 18 months if the failure was unintentional, so check renewal records in diligence.
Swipe or scroll →
What life sciences licensing in Singapore covers
Life sciences licensing in Singapore covers the agreements through which drug candidates, biologics, cell and gene therapies, diagnostics, medical technology, research tools and data move from the people who create them to the companies that develop and sell them. It includes in-licensing and out-licensing of product rights, option and evaluation agreements, university and research-institute technology transfer, platform licences, co-development deals and the supply and regulatory agreements that sit beside them.
Singapore plays several roles in these deals. It is a research base with universities, hospitals and public research institutes that generate licensable IP. It is a regional headquarters and IP-holding location for multinational groups. And it is a neutral contracting and dispute-resolution venue for transactions between parties in Asia, Europe and the Middle East. Each role raises different legal questions.
A licence is only as good as the rights behind it and the regulatory path in front of it. In life sciences, that means patents with enough remaining term, data and materials obtained with proper consent, and a clear answer to who will hold product registrations and run clinical development. This guide focuses on those links between IP, regulation and commercial terms.
The legal and regulatory framework
Patent rights are governed by the Patents Act 1994 and administered by the Intellectual Property Office of Singapore (IPOS). A Singapore patent lasts 20 years from the filing date, subject to annual renewal fees payable from the fourth anniversary of filing. IPOS's patent management guidance notes that the term can run to the end of an extended term where an extension is granted, and that a lapsed patent can be restored within 18 months if the failure to renew was unintentional. Licensees should verify renewal status and any extension as part of diligence.
Licensing also intersects with product regulation. The Health Sciences Authority (HSA) requires the applicant for registration of a therapeutic product to be a local ACRA-registered company and to declare, under regulation 23 of the Therapeutic Products Regulations, whether a subsisting patent would restrain supply. Licence agreements therefore need to decide who will be the Singapore registrant, who prepares the patent declaration and how the registration is transferred if the licence ends.
Human tissue, samples and data
Licences of biological materials, biobank samples and clinical data are shaped by the Human Biomedical Research Act 2015. A core objective of the HBRA framework is preventing commercial trading in human tissue, and future research use generally depends on appropriate consent. MOH's HBR guidance includes specific guidance on the prohibition against commercial trading of human tissue. Personal data in clinical datasets also engages the Personal Data Protection Act 2012, including its rules on transfers overseas.
Competition and tax
Licence restrictions such as exclusivity, territorial limits, non-compete clauses and grant-backs are generally legitimate but can raise issues under the Competition Act 2004 where they go beyond what is needed to protect the licensed technology, particularly between competitors. Royalty and milestone payments to non-resident licensors can attract Singapore withholding tax under the Income Tax Act 1947, subject to treaty relief, so the payment clause should say who bears it and how gross-up works.
Deal structures and how to choose
The right structure depends on the asset's stage, the parties' capabilities and how risk and value should be shared. The main options are compared below.
| Structure | Typical use | Main legal focus |
|---|---|---|
| Exclusive product licence | Licensee takes development and commercial rights for a field and territory | Diligence obligations, milestones, royalties, regulatory ownership, reversion on termination |
| Option or evaluation agreement | Licensee tests the asset before committing | Option period, data access, materials use, pre-agreed licence terms |
| Platform or research tool licence | Non-exclusive use of technology across many programmes | Field limits, reach-through rights, improvements, audit |
| Co-development and co-commercialisation | Parties share costs and profits | Governance committees, cost sharing, deadlock, opt-out rights |
| University or institute technology transfer | Spin-out or company licenses public research | Equity and royalties, publication, background IP, academic use |
| Regional out-licence | Originator grants Asia or ASEAN rights to a partner | Registration ownership, supply, pharmacovigilance, price and parallel trade |
Our patent commercialisation and technology transfer pages cover the wider IP strategy, and our IP licensing page covers licensing outside life sciences.
Key terms in life sciences licensing in Singapore
Grant, field and territory
Define the licensed patents, know-how and materials precisely, and the field and territory in which the licensee may use them. Ambiguity in the field definition is a common source of later disputes.
Diligence obligations
Exclusive licences should require the licensee to develop and commercialise with defined effort, often tied to milestones such as trial starts and regulatory filings, with reversion if they are missed.
Economics
Upfront fees, development and sales milestones, tiered royalties and sublicence income shares. Set royalty terms, stacking and step-downs, and allocate withholding tax clearly.
Regulatory ownership
Decide who sponsors trials, who holds registrations in Singapore and other markets, who owns the dossier and how it transfers on termination.
IP prosecution and enforcement
Allocate control of patent prosecution, maintenance, term extensions, infringement actions and challenges, with cooperation duties and cost sharing.
Improvements and data
Agree ownership of improvements and new data, any grant-back to the licensor, and how clinical and safety data are shared during and after the licence.
Supply, quality and pharmacovigilance agreements
Where the licensor continues to manufacture, the licence sits alongside a supply agreement and a quality agreement. These set forecasting and ordering mechanics, transfer pricing, specifications, batch release, change control and responsibility for recalls. A licensee that becomes the Singapore registrant must be able to meet HSA's requirements, so the quality agreement should give it the information and audit rights it needs, including evidence of GMP at overseas sites.
A pharmacovigilance or safety data exchange agreement is equally important. Each party's regulators expect timely reporting: in Singapore, serious adverse events for therapeutic products must reach HSA within 15 calendar days of awareness. The agreement should fix exchange timelines shorter than the regulatory deadlines, name the holder of the global safety database and allocate signal detection and risk management plan duties.
Exclusivity, sublicensing and change of control
Exclusive licensees usually need the right to sublicense to affiliates, contract manufacturers and regional partners. Licensors will want consent rights or at least notice, flow-down of key obligations and a share of sublicence income. Change-of-control clauses matter in a sector where licensees are frequently acquired: a licensor may not want its asset to pass to a competitor, while the licensee's investors will resist any clause that deters a sale. A balanced position allows assignment on a sale of the business but tightens diligence reporting or allows the licensor to terminate if the acquirer has a directly competing programme.
Termination and reversion
Termination clauses decide what happens to a programme if the deal fails. A licensor will want the rights back with the data, regulatory filings and registrations needed to continue development, sometimes with a licence to the licensee's improvements. A licensee will want compensation for its investment or a royalty on reverted products. Singapore law will generally enforce these clauses as written, so the time to get them right is at signature.
In a life sciences licence, the termination clause is where the value of the programme is really allocated.
Process and timeline for a licensing deal
The sequence below reflects an exclusive product licence with Singapore as a contracting hub. Timelines vary widely with the asset's complexity and the number of parties.
- Confidential disclosure. Sign a confidentiality agreement with a clear purpose, permitted users and residuals position before sharing data.
- Diligence the asset. Review patent ownership, inventor assignments, remaining term, prosecution history, third-party rights, data integrity, consents for samples and data, and regulatory status.
- Agree the term sheet. Fix the grant, field, territory, economics, diligence obligations, regulatory ownership and governing law before drafting.
- Draft and negotiate. Prepare the licence and any ancillary agreements: supply, quality, pharmacovigilance, transitional services and material transfer.
- Clear approvals. Check competition law, tax and any institutional approvals, such as a university's technology transfer office or board.
- Close and transfer. Deliver know-how, materials and documents, record assignments where appropriate and set up the joint steering committee.
- Manage the alliance. Track milestones, reports, audits and patent maintenance, and keep a log of decisions that affect payments.
Documents and diligence evidence
Licensees and investors rely on documents, not assurances. A well-prepared licensor will have the following ready in a data room:
- Patent schedules with filing dates, status, renewal records, any extensions and family members in key markets.
- Inventor assignments and employment or research agreements showing the licensor owns the inventions.
- Prior licences, options, funding agreements and government grant terms that restrict rights or require consents.
- Material transfer agreements and consent documentation for samples, cell lines and datasets.
- Regulatory correspondence, trial approvals, safety data and any HSA Innovation Office advice.
- Freedom-to-operate analyses and any third-party challenge or infringement correspondence.
Two further points deserve attention at this stage. First, check whether any licensed patent family includes Singapore filings at all; many early-stage portfolios are filed only in the US, Europe and China, and the Singapore position may rest on know-how and regulatory data rather than patents. Second, confirm whether the licensor has already granted options, rights of first negotiation or regional rights to others, because these often surface only in board minutes or funding agreements.
Gaps in inventor assignments and consents are the most common diligence findings in early-stage life sciences licensing in Singapore and across the region, and they are much easier to fix before a deal than after.
Licensing from universities, hospitals and public research institutes
Much licensable life sciences IP in Singapore originates in public universities, public hospitals and government research institutes. Their technology transfer offices usually work from standard terms that reserve academic and research use, protect publication, take equity or royalties in spin-outs and limit warranties. Expect fewer warranties than in a commercial deal and plan diligence accordingly.
Clinical collaborations with public hospitals bring additional constraints: data and samples are subject to the HBRA and institutional policies, and ownership of results is governed by the clinical research agreement. Our clinical research agreements page explains how those terms are negotiated, and our guide to life sciences collaboration maps the collaboration models.
For novel therapeutic products and cell and gene therapies, HSA's Innovation Office gives early scientific and regulatory advice without charge. Advice obtained by the licensor can add value to a licence, so the agreement should give the licensee access to it.
Risks and common mistakes
Licensing rights the licensor does not fully own
Academic inventors, consultants and collaborators may own or co-own inventions unless their contracts assign them. Co-owners may be able to exploit or license a patent without each other's consent, depending on the governing law, which can undermine exclusivity. Grant-funded research may carry government or funder rights. Verify the chain of title for every patent and piece of know-how, obtain confirmatory assignments where needed, and give the licensee warranties and remedies that match the risk.
Ignoring consent limits on samples and data
Biological samples and clinical data are often licensed as if they were ordinary assets. Under the HBRA, use of human tissue for research depends on appropriate consent and the framework prohibits commercial trading of human tissue. Personal data in datasets is subject to the PDPA. A licence that grants commercial rights beyond the original consent can expose both parties. Check the consent forms and approvals behind each sample set and dataset, and limit the licence to permitted uses.
Vague diligence obligations
"Commercially reasonable efforts" without a definition, benchmarks or reporting gives the licensor little leverage if the licensee shelves the programme. Licensees, for their part, need flexibility for genuine scientific setbacks. Define the effort standard, link it to specific milestones with dates, require regular development reports and give the licensor a clear termination or conversion right if milestones are missed without good reason.
Leaving the Singapore registration out of the licence
Global licences often deal with US and EU filings in detail and say nothing about Asian registrations. In Singapore, the registrant must be a local company, and the registration is a valuable asset. If the licence does not say who holds it, who prepares the patent declaration and how it transfers on termination, the parties may find that a distributor or affiliate controls a key market. Address registration ownership expressly for each territory.
Royalty clauses that do not survive patent expiry or challenge
Royalties tied only to valid patent claims can fall away if patents expire or are revoked, while royalties extending well beyond expiry can raise enforceability and competition questions. Combined patent and know-how licences need a reasoned royalty step-down. Address what happens if a licensed patent is challenged, including whether the licensee may challenge and the effect on payments, with advice on the governing law.
Cross-border angle
Life sciences licensing in Singapore is usually cross-border. Chinese biotechs increasingly out-license assets to international pharmaceutical companies, and Singapore offers a neutral governing law and seat for those deals. UK and European licensors use Singapore affiliates to manage Asia-Pacific rights. Gulf investors and healthcare groups in the UAE license products for Middle East markets, and Bangladeshi pharmaceutical manufacturers in-license technology and brands for regional generics and contract manufacturing.
Each cross-border deal needs a view on export controls for certain biological materials, data transfer rules, local registration requirements in every territory and tax on cross-border royalties. Disputes are commonly resolved by international arbitration seated in Singapore, which allows confidential, technically informed decisions enforceable in many jurisdictions. Our trade secrets team advises on protecting know-how that cannot be patented.
Before signing a term sheet, write down who will hold the product registration in each key territory and what happens to it on termination. If the parties cannot agree that in one paragraph, they are not ready to negotiate the full licence.
How TRW & Co helps with life sciences licensing in Singapore
We act for licensors, licensees, investors and research institutions on life sciences licensing in Singapore and across our network. We work with patent attorneys on prosecution and validity questions, and where Singapore court or tribunal representation is required, we work alongside Singapore-qualified counsel.
Diligence
We review title, licences, consents, regulatory status and restrictions, and present findings in a form that feeds directly into warranties and price.
Deal structuring and drafting
We prepare term sheets, licences, option, co-development, supply and pharmacovigilance agreements, aligned on regulatory ownership and termination.
Regulatory and data alignment
We map HSA registration, HBRA and PDPA requirements to the licence so that rights granted match what the law and consents allow.
Alliance management and disputes
We advise on milestone, royalty and diligence disputes, audits and terminations, and coordinate arbitration strategy where needed.
See our practices for the wider offering, or contact us about a transaction. Our guide to research and development patent strategy adds detail on building a licensable portfolio.
Checklist for decision-makers
- Do we have clear title to every licensed patent, know-how and material, including inventor assignments?
- How much patent term remains, and are renewals and any extensions in order?
- Do consents and approvals support the intended use of samples and data?
- Are diligence obligations defined, measurable and linked to reversion rights?
- Who holds product registrations in Singapore and other key markets, and how do they transfer?
- Have withholding tax and competition law been reviewed for the payment and restriction clauses?
- Is the dispute resolution clause workable across all parties and territories?
- Is there an alliance management plan for reports, audits and patent maintenance after signing?
Deals that can answer these questions at term sheet stage close faster and are less likely to end in dispute, which is the real test of good life sciences licensing in Singapore.
Frequently asked questions
01Should a licence of a Singapore patent be governed by Singapore law?
Often, but not necessarily. Parties are free to choose the governing law of the contract, and many global licences use New York or English law. The existence, validity and infringement of a Singapore patent will still be determined under Singapore law. Singapore law is a common choice where the licensor is a Singapore institution or the deal covers Asia, and Singapore-seated arbitration is frequently used to resolve disputes confidentially. Choose the governing law and forum together so they work for all parties and territories.
02Who should hold the Singapore product registration under a licence?
HSA requires the registrant to be a local ACRA-registered company. Under an exclusive licence, it is usually the licensee or its local affiliate or distributor. The licence should state who files, who prepares the regulation 23 patent declaration, who maintains the registration and handles variations and safety reporting, and how the registration and dossier transfer to the licensor or a new partner on termination. Without these terms, recovering the registration can be slow and dependent on the cooperation of the outgoing party.
03Can we license biobank samples or clinical data commercially?
Only within the limits of the law and the original consents. The Human Biomedical Research Act framework aims to prevent commercial trading in human tissue, and future research use generally depends on appropriate consent. Personal data in clinical datasets is subject to the PDPA, including transfer restrictions. Licences of samples and data should be limited to permitted uses, priced as cost recovery or access fees where required, and supported by documentation of consent and approvals for each collection.
04What withholding tax applies to royalties paid from Singapore?
Royalties and certain related payments to non-resident licensors can be subject to Singapore withholding tax under the Income Tax Act 1947, with rates that may be reduced under a double tax treaty if conditions are met. Milestone payments may also be caught depending on their character. The licence should state whether payments are made gross or net, who bears the tax, how gross-up works and what documentation the licensor must provide to claim treaty relief. Take tax advice on the specific payment flows.
05What happens to a licence if the patent is revoked?
It depends on the drafting. If royalties are payable only on products covered by a valid claim, revocation may end the royalty obligation for that territory. If the licence also covers know-how, data or materials, royalties may continue at a reduced rate. The agreement should say whether the licensee may challenge the patent, how payments are treated during a challenge and whether revocation in one territory affects others. Competition law can limit no-challenge clauses, so review them carefully.
06How do university spin-out licences differ from commercial licences?
University and public institute licences usually reserve rights for academic research and teaching, protect the right to publish after a review period, limit warranties and indemnities, and often take equity in a spin-out alongside royalties. They may also include diligence milestones and reversion rights to ensure the technology is developed. Founders and investors should check background IP, government grant conditions and conflict-of-interest rules, and negotiate milestone dates that match the financing plan.
Sources and official materials
- Patents Act 1994 — Patent rights, term, licences and transactions
- IPOS: Patents overview — 20-year term and maintenance from the fifth year
- IPOS: Managing patents — Renewal, extension and restoration
- HSA: Therapeutic product registration overview — Local applicant and regulation 23 patent declaration
- Human Biomedical Research Act 2015 — Consent, tissue banking and research governance
- MOH: Regulation of human biomedical research — Guidance including commercial trading of tissue
- HSA: Innovation Office — Early regulatory advice for novel products
General information only, current as at 20 October 2026. It is not legal advice and does not create a lawyer–client relationship. Singapore law and regulatory practice change; check current official sources and take advice on the facts of your matter.
Talk it through
before you decide.
Share the decision, the jurisdictions and the timetable. A partner will tell you what matters, what can wait and what it will take.